Your browser doesn't support javascript.
Antibody Profiling of COVID-19 Patients in an Urban Low-Incidence Region in Northern Germany.
Solbach, Werner; Schiffner, Julia; Backhaus, Insa; Burger, David; Staiger, Ralf; Tiemer, Bettina; Bobrowski, Andreas; Hutchings, Timothy; Mischnik, Alexander.
  • Solbach W; Center for Infection and Inflammation Research, University of Lübeck, Lübeck, Germany.
  • Schiffner J; Health Protection Authority, Lübeck, Germany.
  • Backhaus I; Health Protection Authority, Lübeck, Germany.
  • Burger D; Health Protection Authority, Lübeck, Germany.
  • Staiger R; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Tiemer B; Municipal Statistics Department, Lübeck, Germany.
  • Bobrowski A; Gemeinschaftspraxis Huextertor, Lübeck, Germany.
  • Hutchings T; Laboraerztliche Gemeinschaftspraxis Lübeck, Lübeck, Germany.
  • Mischnik A; Laboraerztliche Gemeinschaftspraxis Lübeck, Lübeck, Germany.
Front Public Health ; 8: 570543, 2020.
Article in English | MEDLINE | ID: covidwho-858827
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
A vast majority of COVID-19 cases present with mild or moderate symptoms. The study region is in an urban and well-defined environment in a low-incidence region in Northern Germany. In the present study, we explored the dynamics of the antibody response with respect to onset, level and duration in patients with confirmed SARS-CoV-2 infection. Anti-SARS-CoV-2 IgG and IgA were detected by automated enzyme-linked immunosorbent assay (ELISA) of SARS-CoV-2 infected patients monitored by the Health Protection Authority. This explorative monocentric study shows IgA and IgG antibody profiles from 118 patients with self-reported mild to moderate, or no COVID-19 related symptoms after laboratory-confirmed infection with SARS-CoV-2. We found that 21.7% and 18.1% of patients were seronegative for IgA or IgG, respectively. Clinically, most of the seronegative patients showed no to only moderate symptoms. With regard to antibody profiling 82% of all patients developed sustainable antibodies (IgG) and 78% (IgA) 3 weeks or later after the infection. Our data indicate that antibody-positivity is a useful indicator of a previous SARS-CoV-2 infection. Negative antibodies do not rule out SARS-CoV-2 infection. Future studies are needed to determine the functionality of the antibodies in terms of neutralization capacity leading to personal protection and prevention ability to transmit the virus as well as to protect after vaccination.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal: Front Public Health Year: 2020 Document Type: Article Affiliation country: Fpubh.2020.570543

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal: Front Public Health Year: 2020 Document Type: Article Affiliation country: Fpubh.2020.570543